Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$159.62 USD

159.62
10,721,183

-7.67 (-4.58%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $160.06 +0.44 (0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ABBV

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for AbbVie Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 12,816 9,229 9,830 8,479 39,924
Receivables 11,155 11,254 9,977 8,822 5,428
Notes Receivable 0 0 0 0 0
Inventories 4,099 3,579 3,128 3,310 1,813
Other Current Assets 4,932 4,401 4,993 3,562 2,354
Total Current Assets 33,002 28,463 27,928 24,173 49,519
Net Property & Equipment 4,989 4,935 5,110 5,248 2,962
Investments & Advances 304 241 277 293 93
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 87,903 99,595 108,330 116,000 34,253
Deposits & Other Assets 8,513 5,571 4,884 4,851 2,288
Total Assets 134,711 138,805 146,529 150,565 89,115
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 30,650 25,402 22,699 20,159 11,832
Current Portion Long-Term Debt 7,191 4,136 12,495 8,502 3,753
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 37,841 29,538 35,194 28,661 15,585
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1,952 2,190 3,009 3,646 1,130
Convertible Debt 0 0 0 0 0
Long-Term Debt 52,194 59,135 64,189 77,554 62,975
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 32,327 30,655 28,701 27,607 17,597
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 124,314 121,518 131,093 137,468 97,287
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 18 18 18 18 18
Capital Surplus 20,180 19,245 18,305 17,384 15,193
Retained Earnings -1,000 4,784 3,127 1,055 4,717
Other Equity -2,268 -2,166 -2,871 -3,096 -3,596
Treasury Stock 6,533 4,594 3,143 2,264 24,504
Total Shareholder's Equity 10,397 17,287 15,436 13,097 -8,172
Total Liabilities & Shareholder's Equity 134,711 138,805 146,529 150,565 89,115
Total Common Equity 10,397 17,287 15,436 13,097 -8,172
Shares Outstanding 1,800.00 1,768.40 1,767.10 1,765.40 1,478.80
Book Value Per Share 5.78 9.78 8.74 7.42 -5.53

Fiscal Year End for AbbVie Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 12,816 13,290 8,766 6,722
Receivables NA 11,155 11,412 11,491 11,473
Notes Receivable NA 0 0 0 0
Inventories NA 4,099 3,981 4,055 3,833
Other Current Assets NA 4,932 4,541 4,540 4,460
Total Current Assets NA 33,002 33,224 28,852 26,488
Net Property & Equipment NA 4,989 4,934 4,943 4,931
Investments & Advances NA 304 275 288 257
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 87,903 90,694 95,086 97,068
Deposits & Other Assets NA 8,513 7,094 6,198 5,800
Total Assets NA 134,711 136,221 135,367 134,544
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 30,650 29,658 27,036 24,789
Current Portion Long-Term Debt NA 7,191 5,115 5,203 2,801
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 37,841 34,773 32,239 27,590
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 1,952 2,044 2,124 2,110
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 52,194 55,631 55,812 59,292
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 31,644 32,294 32,249
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 124,314 124,092 122,469 121,241
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 18 18 18 18
Capital Surplus NA 20,180 20,021 19,839 19,619
Retained Earnings NA -1,000 933 1,789 2,393
Other Equity NA -2,268 -2,318 -2,220 -2,203
Treasury Stock NA 6,533 6,525 6,528 6,524
Total Shareholder's Equity NA 10,397 12,129 12,898 13,303
Total Liabilities & Shareholder's Equity NA 134,711 136,221 135,367 134,544
Total Common Equity 0 10,397 12,129 12,898 13,303
Shares Outstanding 1,770.60 1,800.00 1,765.50 1,764.20 1,764.20
Book Value Per Share 0.00 5.78 6.87 7.31 7.54